ABSI
Absci Corp
NASDAQ · Healthcare · Biotechnology · US
$9.65
+4.10%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$9.27
From 52W high−16.95%
Volume7.64M
Market cap$1.66B
P/E (TTM)—
P/S (TTM)1060.9x
Div yield—
Key dataSep 18, 2026
Open
$9.27
From 52W high
−16.95%
Volume
7.64M
Market cap
$1.66B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.3x
P/E (TTM)
—
RSI (14)
58.2
MomentumView details →
1D Return
+4.10%
YTD Return
+170.49%
SummaryUpdated Jun 1, 2026
Absci Corporation (NASDAQ:ABSI) is a biotechnology company founded in 2011 and headquartered in Vancouver, Washington. The company went public in July 2021 and operates as a drug and target discovery company that leverages artificial intelligence to create biologic drug candidates. Absci has developed an integrated drug creation platform that unifies traditional drug discovery and cell line development processes, enabling the design of antibodies for previously challenging or "undruggable" targets.
Similar companies
Latest newsMore news →
Eli Lilly is making strategic investments in outside companies such as Absci Corp., which is developing an experimental endometriosis therapy, as part of its expansion into women's health.10d agoAbsci completed a $100 million underwritten offering, including a $40 million strategic investment from Eli Lilly and Company.40d agoAbsci Corporation reported financial and operating results for the second quarter of 2026.40d ago